130 related articles for article (PubMed ID: 25790318)
1. Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case.
Ryan EH; Pulido CM
Retin Cases Brief Rep; 2015; 9(3):235-8. PubMed ID: 25790318
[TBL] [Abstract][Full Text] [Related]
2. SPIRONOLACTONE AS A THERAPEUTIC ALTERNATIVE FOR THE BULLOUS VARIANT OF CENTRAL SEROUS CHORIORETINOPATHY.
Ramos-Yau EC; Muñoz-Domínguez E; Contreras-Mérida SP; Valencia-Londoño LM
Retin Cases Brief Rep; 2020; 14(4):381-385. PubMed ID: 29595560
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C
Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785
[TBL] [Abstract][Full Text] [Related]
4. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy.
Breukink MB; den Hollander AI; Keunen JE; Boon CJ; Hoyng CB
Acta Ophthalmol; 2014 Sep; 92(6):e488-90. PubMed ID: 24698599
[No Abstract] [Full Text] [Related]
5. Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy.
Bousquet E; Dhundass M; Lejoyeux R; Shinojima A; Krivosic V; Mrejen S; Gaudric A; Tadayoni R
Am J Ophthalmol; 2019 Feb; 198():80-87. PubMed ID: 30308202
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.
Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F
Retina; 2013; 33(10):2096-102. PubMed ID: 23719402
[TBL] [Abstract][Full Text] [Related]
7. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series.
Salz DA; Pitcher JD; Hsu J; Regillo CD; Fineman MS; Elliott KS; Vander JF; Fischer DH; Spirn MJ
Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):439-44. PubMed ID: 25970864
[TBL] [Abstract][Full Text] [Related]
8. Eplerenone in patients with chronic recurring central serous chorioretinopathy.
Leisser C; Hirnschall N; Hackl C; Plasenzotti P; Findl O
Eur J Ophthalmol; 2016 Aug; 26(5):479-84. PubMed ID: 26692062
[TBL] [Abstract][Full Text] [Related]
9. Spironolactone in the treatment of central serous chorioretinopathy - a case series.
Herold TR; Prause K; Wolf A; Mayer WJ; Ulbig MW
Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1985-91. PubMed ID: 25138605
[TBL] [Abstract][Full Text] [Related]
10. SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY.
Bousquet E; Beydoun T; Rothschild PR; Bergin C; Zhao M; Batista R; Brandely ML; Couraud B; Farman N; Gaudric A; Chast F; Behar-Cohen F
Retina; 2015 Dec; 35(12):2505-15. PubMed ID: 26017871
[TBL] [Abstract][Full Text] [Related]
11. A new treatment approach - Eplerenone - in central serous chorioretinopathy - Case report.
Cioboata M; Alexandrescu C; Hopinca CA; Pienaru MC; Merticariu A; Schmitzer S
J Med Life; 2016; 9(1):92-94. PubMed ID: 27713772
[TBL] [Abstract][Full Text] [Related]
12. CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY.
Ghadiali Q; Jung JJ; Yu S; Patel SN; Yannuzzi LA
Retina; 2016 Mar; 36(3):611-8. PubMed ID: 26405766
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy.
Sun X; Shuai Y; Fang W; Li J; Ge W; Yuan S; Liu Q
Br J Ophthalmol; 2018 Aug; 102(8):1060-1065. PubMed ID: 29089356
[TBL] [Abstract][Full Text] [Related]
14. The relation of the serum aldosterone level and central serous chorioretinopathy - a pilot study.
Gong Q; Sun XH; Yuan ST; Liu QH
Eur Rev Med Pharmacol Sci; 2017 Feb; 21(3):446-453. PubMed ID: 28239828
[TBL] [Abstract][Full Text] [Related]
15. Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy.
Yang D; Eliott D
Semin Ophthalmol; 2017; 32(1):36-42. PubMed ID: 27929707
[TBL] [Abstract][Full Text] [Related]
16. Lack of efficacy of eplerenone for treatment of active central serous chorioretinopathy.
Sadda SR
Eye (Lond); 2020 Sep; 34(9):1489-1490. PubMed ID: 32042181
[No Abstract] [Full Text] [Related]
17. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR).
Rahimy E; Pitcher JD; Hsu J; Adam MK; Shahlaee A; Samara WA; Vander JF; Kaiser RS; Chiang A; Spirn MJ; Fineman MS
Retina; 2018 May; 38(5):962-969. PubMed ID: 28426624
[TBL] [Abstract][Full Text] [Related]
18. Investigating the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy.
Yavuz S; Balsak S; Karahan M; Dursun B
J Fr Ophtalmol; 2021 Jan; 44(1):13-23. PubMed ID: 33279285
[TBL] [Abstract][Full Text] [Related]
19. The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy.
Pociej-Marciak W; Karska-Basta I; Ozog-Baran J; Kubicka-Trzaska A; Filemonowicz-Skoczek A; Romanowska-Dixon B
Klin Oczna; 2016 Aug; 118(1):48-54. PubMed ID: 29715409
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.
Pichi F; Carrai P; Ciardella A; Behar-Cohen F; Nucci P;
Int Ophthalmol; 2017 Oct; 37(5):1115-1125. PubMed ID: 27757733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
